Dr. Edgardo Santos' Interview with Toni Choueiri, MD
Update: 2025-08-25
Description
Interviews withSummit Director Edgardo S. Santos Castillero, MD, FACP, FASCO at NOSCM at 2024 | New Orleans Summer Cancer Meeting
Dr. Edgardo Santos' Interview with Toni Choueiri, MD
Dr. Choueiri highlighted pembrolizumab as the first adjuvant immunotherapy approved for intermediate-high and high-risk kidney cancer—demonstrating overall survival benefits—and confirmed that first-line nivolumab plus ipilimumab improves outcomes, whereas PD-1 rechallenge after progression is unsupported. He also presented HIF-2 inhibitors like belzutifan, which have shown notable progression-free survival gains in phase 3 trials.
Comments
In Channel